Detection of Amplified Her2/Neu Gene Score 2 Cases in Breast Cancer Using Chromogenic In Situ Hybridization

Both Her2 gene and Her2 protien are part of normal cell growth they seen in the breast cells of people without cancer, but sometime mistakes in a cell DNA and mutation cause the body to create many HER2 proteins. For diagnosis of HER-2/neu gene amplification, A total of 60 paraffin embedded breast tumors block from women with final histopathology diagnosis of invasive ductal breast carcinoma. All these samples were chosen as scored 2+ (equivocal) Her-2/neu by using Immunohistochemistry (IHC) technique. CISH as molecular method to detect Her-2/neu gene amplification was used. The high number and percentage (33/55%) of the breast cancer cases were found in pre-menopause Group < 50 years old. The highest number of the breast cancer cases grade ll was must common (42/70%). There were significant differences between age groups and between all histological grades. Stage IIIA was the highest one (25/41.7%) with significant differences between all stages. Using chromogenic in situ hybridization methods to detect HER2/neu gene the amplified cases were (36.6%). There were high significant differences between age, tumor grade and stage within amplified cases. CISH is hopeful to detect gene expression when the HER2/neu is score 2 (equivocal). It is valuable and considerable when correlated its results with the age, tumor grade and stage.